

1 **Retrospective Analysis of Neonatal Hyperbilirubinemia at Hiwot Fana Specialized Hospital, Ethiopia:**
2 **Prevalence, Associated Factors, and Treatment Outcomes**

3 **Authors:**

4 **Mohamed Abdirahman Shugri¹, Temesgen Teferi Libe^{2*}, Feven Mekonnen Gebru³**

5 **Affiliations:**

6 ¹School of Medicine, College of Health and Medical Sciences, Jigjiga University, Eastern, Ethiopia.

7 ²Department of Pediatrics and Child Health, College of Health and Medical Sciences, Haramaya University,
8 Harar, Ethiopia.

9 ³ Abinet Health Centre, Addis Abeba Health bureau, Addis Abeba, Ethiopia.

10 *Corresponding author

11 **Contact details**

12 ¹dr.barud@gmail.com

13 ^{2*}libe.temesgen.temesgen@gmail.com

14 ³fevimekonnen13@gmail.com

15

Abstract

Background: Neonatal hyperbilirubinemia, also known as neonatal jaundice, is a condition characterized by yellowish discoloration of the skin and eyes caused by bilirubin buildup in the body. Understanding its prevalence, associated factors, and outcomes is crucial for effective management.

Objectives: This study aimed to assess the prevalence, associated factors, and treatment outcomes of neonatal hyperbilirubinemia at Hiwot Fana Specialized Hospital, Eastern Ethiopia.

Methodology: A hospital-based cross-sectional study was conducted from December 1, 2020, to December 30, 2020, involving 328 neonates admitted to the Neonatal Intensive Care Unit. Data were collected using a checklist and analyzed using SPSS version 22.

Result: Neonatal hyperbilirubinemia prevalence was 44.2%, with 1.4% progressing to bilirubin encephalopathy. Sepsis (44.8%) and prematurity (22%) were major contributing factors. Most neonates were treated with phototherapy alone (82.3%), and 93.8% showed improvement.

Conclusion: The study underscores the importance of early detection and management of neonatal hyperbilirubinemia to prevent adverse outcomes. Recommendations include integrating jaundice prevention into antenatal care and ensuring timely bilirubin level checks in neonates.

Key Words: Neonatal hyperbilirubinemia, Prevalence, Associated factors, Treatment outcomes, Eastern Ethiopia

33 1. INTRODUCTION

34 1.1. Background

35 Neonatal hyperbilirubinemia, also known as neonatal jaundice, is a condition characterized by a
36 yellowish discoloration of the skin, sclera, and mucous membranes, stems from the accumulation
37 of bilirubin in the body [1]. This condition manifests when serum bilirubin levels exceed
38 $85\mu\text{mol/l}$ (5mg/dl), primarily due to heightened bilirubin production from senescent fetal red
39 blood cells and the infant's limited capacity to eliminate bilirubin effectively [2].

40 Of significant concern is the potential for kernicterus, a form of bilirubin encephalopathy, which
41 arises from unconjugated hyperbilirubinemia. Kernicterus can result from hemolytic diseases
42 like Rh incompatibility or deficiencies in the liver's ability to conjugate bilirubin due to
43 enzymatic defects[3]. Its clinical manifestations span from acute to chronic phases, with
44 symptoms such as hypotonia, poor feeding, high-pitched cry, and, in severe cases, cerebral palsy,
45 sensory-neural deafness, seizures, and neurocognitive impairment [4].

46 Globally, neonatal jaundice affects a substantial proportion of newborns, with up to 60% of term
47 and 80% of preterm infants experiencing it within their first week of life [5].

48 Studies across various regions have reported varying incidences of neonatal hyperbilirubinemia,
49 with Pakistan and Nigeria documenting rates of 27.6% and 19.6%, respectively [6].

50 Contributing to these elevated bilirubin levels are factors such as infection, ABO incompatibility,
51 and glucose-6-phosphate dehydrogenase (G6PD) deficiency [7].

52 In Ethiopia, neonatal jaundice poses a significant threat, with prevalent factors including
53 neonatal sepsis, preterm birth, hypoxia, and acidosis exacerbating the risk of acute bilirubin

54 encephalopathy [8]. Despite its prevalence and associated morbidity, there's a scarcity of
55 comprehensive studies exploring the burden and determinants of neonatal jaundice in Ethiopia,
56 particularly in the study area of Hiwot Fana Specialized University Hospital, Eastern Ethiopia.
57 This study seeks to address this gap by investigating the incidence of neonatal jaundice and its
58 associated factors among neonates admitted to the neonatology unit at Hiwot Fana Specialized
59 University Hospital. Understanding the epidemiology and determinants of neonatal jaundice in
60 this context is crucial for several reasons.

61 Firstly, it provides vital insights for hospital protocols, enabling the development of targeted
62 strategies for the prevention and management of neonatal hyperbilirubinemia. By identifying
63 modifiable risk factors and early treatment options, healthcare providers can optimize care
64 delivery and improve neonatal outcomes within the hospital setting.

65 Secondly, the findings of this study have broader implications for regional health policies and
66 programs. Harari Regional Health Bureau and other stakeholders can leverage this data to
67 formulate evidence-based interventions aimed at reducing the burden of neonatal jaundice and
68 improving neonatal health outcomes in the region.

69 Lastly, this study contributes to the existing body of knowledge on neonatal jaundice, serving as
70 a resource for future research endeavors in this field. Researchers and practitioners alike can
71 build upon these findings to deepen our understanding of the epidemiology, etiology, and
72 management of neonatal jaundice, both within Ethiopia and beyond.

73 **1.2. Objectives**

74 **General objective**

75 To assess prevalence, associated factors, and treatment outcome of Neonatal Hyperbilirubinemia
76 among neonates admitted to Hiwot Fana Specialized University Hospital, Eastern Ethiopia from
77 January 2019 to December 2020.

78 **Specific Objectives:**

79 1. To determine prevalence of Neonatal Hyperbilirubinemia among neonates admitted to
80 Hiwot Fana Specialized Hospital.

81 2. To assess factors associated with Neonatal Hyperbilirubinemia among neonates admitted
82 to Hiwot Fana Specialized Hospital

83 3. To determine treatment outcome of Neonatal Hyperbilirubinemia among neonates
84 admitted to Hiwot Fana Specialized Hospital.

85 **2. Methodology**

86 **2.1 Study area and period**

87 This study took place at Hiwot Fana Comprehensive Specialized Hospital (HFCSH), a teaching
88 hospital affiliated with Haramaya University in Harar town, Harari Region, Ethiopia. HFCSH
89 serves as a referral center for Eastern Ethiopia, catering to a population of approximately 5.8
90 million people, including residents of the Harari Region, Dire Dawa City Administration, Somali
91 Region, and the Eastern Hararghe Zone of the Oromia Regional State. According to unpublished
92 Health Management Information System data from 2020, HFCSH admits around 3,000 pediatric
93 patients annually, half of whom are neonates. Additionally, the hospital conducts approximately
94 5,500 deliveries each year.

95 The study was conducted from December 1, 2020, to December 30, 2020.2.2.

96 **2.2. Study design**

97 A hospital-based cross-sectional study design was employed.

98 **2.3 populations**

99 **2.3.1 Source population**

100 The source population included all neonates admitted to the Neonatal Intensive Care Unit
101 (NICU) of HFCSH from January 1, 2019, to December 30, 2020.

102 **2.3.2 Study population**

103 The study population comprised selected neonates among those admitted to the NICU of HFCSH
104 during the same period.

105 **2.4. Inclusion and exclusion criteria**

106 **2.4.1 Inclusion Criteria**

107 All neonates of age group from birth to 28 days who were admitted to NICU of Hiwot Fana
108 Specialized Hospital during the study period.

109 **2.4.2 Exclusion Criteria**

110 Patients diagnosed with neonatal jaundice but with incomplete charts or without a recorded
111 serum bilirubin level were excluded from the study.

112 **2.5. Sample size determination and sampling technique**

113 **2.5.1 Sample Size determination**

114 **Objective 1:** Prevalence of Neonatal Jaundice

115 A single population proportion formula was employed, considering a prevalence (p) of 44.9%
 116 from a previous study conducted at Black Lion Hospital (Kassa et al., 2018). We aimed for a
 117 95% confidence interval and a 5% degree of precision. To account for a potential 5% non-
 118 response rate, the initial sample size was adjusted accordingly. This calculation resulted in a final
 119 sample size of 328.

120 **Objective 2:** Associated Factors of Neonatal Jaundice

121 For the second objective, which focused on identifying factors associated with neonatal jaundice,
 122 a double population proportion formula was used. Sample sizes for specific factors were
 123 calculated using OpenEpi data statistical software version 3.1. The calculations assumed a 95%
 124 confidence level, 80% power, and a ratio of unexposed to exposed neonates close to 1 (data from
 125 different literature sources was used for these calculations). (Table 1)

126 Table 1: Sample size determinations using double population proportions formula for the second
 127 objective.

Factors	Neonatal jaundice		Odds ratio	Non-response rate	Sample size	Reference
	Exposed	Non-exposed				
Sepsis	49	27	2.64	10%	170	[9]
Blood group incompatibility	84.8	23.9	18.21	10%	26	[9]
Duration of labor	34	44	4.39	10%	76	[10].
Place of delivery	36.4	44.3	4.37	10%	78	[10].

128

129 The larger sample size, 328, was taken as final sample size.

130 **2.5.2 Sampling techniques**

131 A systematic sampling method was employed, selecting every 6th value among neonates
132 admitted to the NICU of HFCSH from January 1, 2019, to December 30, 2020.

133 **2.6. Data collection method**

134 **2.6.1. Data collection tool and procedure**

135 A checklist developed in the English language, containing variables to be measured, was utilized.
136 The checklist was adapted from various literature sources [9, 10]. Neonatal admission cards from
137 the NICU of HFCSH were isolated and counted, and their numbers were arranged in the order of
138 admission. Data collection involved systematically collecting necessary information from every
139 6th value in the order.

140 **2.6.2 Data collectors**

141 Two BSc nurses and one resident were trained and recruited as data collectors under the
142 supervision of the principal investigator.

143 **2.7 Study variable**

144 **2.7.1 Dependent variables**

- 145 • Neonatal jaundice.
- 146 • Treatment outcome

147 **2.7.2 Independent variables**

- 148 • Maternal factors: blood group and Rh, antenatal care (ANC) follow-up.
- 149 • Neonatal factors: age, gestational age, birth weight, blood group and Rh, hematocrit, total
- 150 serum bilirubin (TSB), mode of delivery, birth trauma, breast milk jaundice, sepsis,
- 151 breastfeeding.

152 **2.9. Data quality control**

153 Measures were taken to ensure the validity and reliability of data collection, including training of
154 data collectors, pre-testing of the questionnaire, supervision during data collection, and double
155 data entry with consistency checks.

156 **2.10. Methods of data analysis**

157 The collected data underwent a thorough cleaning process to ensure completeness before being
158 entered into EPI Data version 8.1. This process involved coding, cleaning, and editing to
159 minimize logical errors and prevent skipping patterns in the data entry. Subsequently, the data
160 was exported to SPSS version 22 for analysis. Descriptive statistics were employed to summarize
161 the data. This included calculating proportions and other summary measures, which were then
162 presented using simple frequencies, tables, and figures.

163 To investigate the associations between independent and dependent variables, both bivariate and
164 multivariate analyses were conducted using binary logistic regression. The assumptions for the
165 binary logistic regression model were verified. Goodness-of-fit was assessed using the Hosmer-
166 Lemeshow statistic and omnibus tests.

167 Variables with a p-value less than 0.25 in the bivariate analysis were included in the final model
168 of the multivariate analysis. This approach helped control for potential confounding factors. The

169 direction and strength of the statistical associations were measured by calculating odds ratios
170 with 95% confidence intervals (CI). Multivariate analysis using binary logistic regression was
171 employed to estimate adjusted odds ratios (also with 95% CI) to identify independent predictors
172 for neonatal jaundice and its associated factors. In this study, a p-value less than 0.05 was
173 considered statistically significant.

174 **2.11. Ethical consideration**

175 Ethical approval was obtained from the Institutional Research Ethics Review Committee
176 (IHRERC) of Haramaya University. Informed consent was obtained from participants, and
177 confidentiality was maintained throughout the study.

178 **3. RESULT OF THE STUDY**

179 **3.1. Socio-demographic characteristics of neonates in the study, HFSUH.**

180 In a retrospective cross-sectional study, 328 neonates were systematically selected from all
181 neonates admitted to the NICU of HFSUH from January 1, 2020, to December 30, 2020, to
182 evaluate the magnitude and associated factors of neonatal hyperbilirubinemia. Of these, 176
183 (53.7%) were male and 152 (46.3%) were female. Among the neonates included, 145 (44.2%)
184 developed neonatal hyperbilirubinemia. At the time of admission, 138 (42%) neonates were aged
185 3-6 days, and 247 (75.3%) weighed between 2500gm-4000g. The duration of hospital stays
186 ranged from 1 to 31 days, with 211 (64.3%) discharged within a week and 10 (10.6%)
187 discharged after 21 days. Premature neonates accounted for 116 (35.4%), and 60 (18.3%)
188 neonates' mothers did not know their gestational age. (Table 2)

189

190

191 Table 2: Socio-demographic characteristics of Admitted Neonates

Socio-demographic characteristics	Category	Frequency/percent; among all neonates (328)	Frequency(percent); Jaundiced Neonates
Sex	Male	176(53.7%)	89(61.4%)
	Female	152(46.3%)	56(38.6%)
Age at admission (days)	<= 2	93(28.4%)	21(14.5%)
	3-6	138(42%)	65(44.8%)
	> 6	97(29.6%)	59(40.7%)
Weight (grams)	< 2500	71(21.6%)	21(14.5%)
	2500-4000	247(75.3%)	118(81.4%)
	>= 4000	10(3.1%)	6(4.1%)
Gestational age (weeks)	< 37 weeks	116(35.4%)	36(24.8%)
	>= 37 weeks	152(46.3%)	70(48.3%)
	Unknown	60(18.3%)	39(29.9%)

192

193 3.2. Magnitude of neonatal hyperbilirubinemia

194 Neonatal hyperbilirubinemia was diagnosed in 145 (44.2%) of the reviewed neonates. Only 2
 195 (1.4%) cases progressed to bilirubin encephalopathy. Males had a higher prevalence of
 196 hyperbilirubinemia compared to females (61.4% vs. 38.6%). The most common age group for
 197 presentation with jaundice was 3-6 days old (44.8%). Neonates weighing 2500-4000gm at
 198 admission were most likely to develop jaundice (81.4%). Prematurity was a contributing factor
 199 in 35.4% of jaundiced neonates. The majority (60%) of these neonates were discharged within
 200 the first week after admission. The most frequent onset of jaundice occurred between 3 and 6
 201 days after birth (44.8%). Less frequent jaundice onset occurred ≤ 3 days (14.5%) or > 6 days

202 (40.7%) after birth.

203 In terms of serum bilirubin levels, 33 (22.8%) neonates had levels ≥ 20 mg/dL, while 83 (57.2%)
204 had levels between 10mg/dL-20mg/dL. Notably, both neonates with bilirubin encephalopathy
205 had serum bilirubin levels of 28mg/dL and 25mg/dL. (Table 2)

206 **3.3. Associated factors of neonatal hyperbilirubinemia**

207 Sepsis (44.8%) and prematurity (22.0%) were the major causes of neonatal hyperbilirubinemia in
208 this study. Hemolytic disease caused by Rh incompatibility (4.8%) and ABO incompatibility
209 (10.3%) were also identified as contributing factors (Table 3). Multiple contributing factors were
210 identified in 16 (11.0%) neonates with elevated bilirubin levels. The most common combinations
211 were ABO incompatibility combined with prematurity (6.2%) and sepsis combined with
212 prematurity (3.8%). Both neonates with bilirubin encephalopathy had multiple contributing
213 factors.

214 Sepsis was a leading cause of neonatal hyperbilirubinemia; however, blood cultures were only
215 performed in 2 neonates, and both cultures were positive.

216 Binary logistic regression analysis identified several factors significantly associated with the
217 development of neonatal hyperbilirubinemia. Neonates admitted at ≤ 2 days old were 5.3 times
218 more likely (OR = 5.323, 95% CI: 2.823-10.039, p-value=0.000) to develop hyperbilirubinemia
219 compared to those admitted after 6 days old. Similarly, neonates with a birth weight less than
220 2500 grams were 3.6 times more likely (OR = 3.571, 95% CI: 0.913-13.970, p-value=0.067) to
221 experience hyperbilirubinemia compared to those weighing 4000 grams or more. Premature birth
222 (gestational age less than 37 weeks) was also a significant risk factor, with neonates in this group
223 being 4.1 times more likely (OR = 4.127, 95% CI: 2.132-7.988, p-value=0.000) to develop
224 hyperbilirubinemia compared to neonates with unknown gestational age.

225 However, multivariate logistic regression analysis only confirmed a significant association
 226 between neonatal hyperbilirubinemia and gestational age. Premature birth (gestational age less
 227 than 37 weeks) remained a significant risk factor, with neonates in this group being 3.8 times
 228 more likely (AOR = 3.821, 95% CI: 1.745-8.368, p-value=0.001) to develop hyperbilirubinemia
 229 compared to those born at 37 weeks or later (Table 3)

230 Table 3: Bivariate and multivariate regression for associated factors with neonatal
 231 hyperbilirubinemia

Variables	Neonatal jaundice		95% CI		P-value
	Yes	No	COR	AOR	COR AOR
Sex					
Male	89(61.4%)	87(47.5%)	1.754(1.126-2.730)	0.356(0.277-1.036)	.013
Female	56(38.6%)	96(52.5%)	1	1	0.064
GA					
<37 wks	36(24.8%)	80(43.7%)	4.127(2.132-7.988)	3.821(1.745-8.36)	0.000
>=37 wks	70(48.3%)39(26.9%)	82(44.8%)	1	1	0.001
Weight/gram					
<2500	21(14.5%)	50(27.3%)	3.571(0.913-13.97)	1.479(0.339-6.45)	0.067
2500-4000	118(81.4%)	129(70.5%)	1	1	0.603
>4000	6(4.1%)	4(2.2%)	1.640(0.45-5.954)	0.410(0.096-1.75)	0.452 0.229
Age in day					
<=2	21(14.5)	72(39.3%)	5.323(2.823-10.03)	1.479(0.339-6.45)	0.000
3-6	65(44.8%)	73(39.9%)	1.744(1.029-2.954)	0.410(0.096-1.75)	0.000
>6	59(40.7%)	38(20.8%)	1	1	0.039 0.426

232 **3.4. Condition at discharge and management of neonates with hyperbilirubinemia**

233 Most jaundiced neonates were treated with either phototherapy alone (82.3%) or a
234 combination of phototherapy and blood transfusion (7.6%). Two neonates with planned
235 exchange transfusions did not receive them due to a blood shortage at the hospital at the
236 time of admission. One of these neonates with bilirubin encephalopathy died. Neonatal
237 death due to bilirubin encephalopathy occurred in 2 cases (1.4%) among those with
238 hyperbilirubinemia. Overall, 93.8% of jaundiced neonates improved and were discharged
239 home. However, 7 (4.8%) left against medical advice.

240

241 **4. DISCUSSION**

242 This study revealed a high prevalence of neonatal hyperbilirubinemia, with 145 (44.2%) cases
243 identified, of which 2 (1.4%) neonates developed bilirubin encephalopathy. These findings were
244 comparable to other studies conducted in Ethiopia, which reported a prevalence of 37.3% [10]
245 and 44.9% [9]. However, the prevalence in this study was significantly higher compared to
246 studies from other parts of the world, such as 13.3% [11], 27.6% [6] and 24.8% [12]. This
247 disparity may be attributed to differences in study areas or socio-demographic characteristics.

248 The study also found that neonatal death due to neonatal hyperbilirubinemia was 2 (1.4%), both
249 of which were attributed to bilirubin encephalopathy. This underscores the seriousness of
250 hyperbilirubinemia, leading to long-term sequelae in survivors and death in neonates. These
251 findings align with research by Aboyans and Collaborators [13], which highlighted the
252 increasing recognition of neonatal hyperbilirubinemia as a significant contributor to global
253 neonatal mortality.

254 Furthermore, significant associations were found between neonatal hyperbilirubinemia and
255 gestational age. The study revealed that 70.4% of neonates developed hyperbilirubinemia in the
256 first week of life. Similar findings were observed in studies conducted in various regions,
257 indicating a consistent trend of neonatal hyperbilirubinemia onset within the early postnatal
258 period. Among the associated factors identified in this study, sepsis (44.8%) and prematurity
259 (22%) were prominent contributors to neonatal hyperbilirubinemia. Other contributing factors
260 included ABO incompatibility (10.3%), Rh incompatibility (4.8%), breastfeeding (8.9%), and
261 other known causes (15.9%).

262 Comparisons with similar studies revealed similarities and differences in associated factors. For
263 instance, a study conducted at Black Lion Hospital in 2017 found ABO incompatibility (35.6%)
264 and sepsis (18.8%) to be major associated factors. Meanwhile, a study in West India University
265 in 2012 identified ABO incompatibility (35%), prematurity (11%), Rh incompatibility (3.5%),
266 and idiopathic causes (9%) as significant factors. The prevalence of ABO incompatibility was
267 consistent across studies, suggesting its importance in neonatal hyperbilirubinemia.

268 Additionally, challenges in early detection of hyperbilirubinemia were noted, particularly in
269 neonates whose mothers lacked antenatal follow-up and did not know their gestational age. This
270 could lead to delays in diagnosis and increased complications. Moreover, the study highlighted
271 the association between elevated serum bilirubin levels and the presence of multiple associated
272 factors, indicating a cumulative effect on bilirubin levels

273 In terms of management, the majority of jaundiced neonates received phototherapy alone, while
274 a smaller proportion required a combination of phototherapy and blood transfusion. Challenges
275 in access to exchange transfusion due to blood shortages were noted, underscoring the need for
276 improved healthcare infrastructure and resources.

277 **Limitation and the Strength of the study**

278 **Strength:** This study benefited from well-maintained medical records, allowing researchers to
279 obtain accurate information related to neonatal hyperbilirubinemia.

280 **Limitation:** However, the retrospective nature of the study limited the ability to locate and
281 follow up with discharged subjects to determine if they developed long-term complications.
282 Additionally, the study's single-site design and limited sample size restrict the generalizability of
283 the findings to other institutions.

284 **6. CONCLUSION**

285 The study findings highlight the significant burden of neonatal hyperbilirubinemia at Hiwot Fana
286 Specialized University Hospital, Eastern Ethiopia. Sepsis, prematurity, and other associated
287 factors contribute to the high prevalence of this condition. Effective management strategies,
288 including phototherapy and blood transfusions, play a crucial role in improving outcomes for
289 affected neonates. However, challenges such as blood shortages pose barriers to optimal care
290 delivery.

291 **AKNOWLEDGMENTS**

292 We would like to express our sincere gratitude to Haramaya University for their invaluable
293 support. This includes both the ethical clearance they provided and the technical and financial
294 assistance they offered.

295 **Data Sharing Statement**

296 Any of the data used for analysis in the study is available from the corresponding author and
297 ready to be provided up on reasonable request.

298 **Conflict of interest:** There is no competing interest.

299 **Contribution of authors:**

300 Conceptualization: Mohamed A Shugri, Temesgen T Libe, Feven M Gebru; formal analysis:
301 Mohamed A Shugri, Temesgen T Libe, Feven M Gebru; investigation: Mohamed A Shugri,
302 Temesgen T Libe; methodology: Mohamed A Shugri, Temesgen T Libe, Feven M Gebru;
303 Validation: Mohamed A Shugri, Temesgen T Libe; writing the original draft: Mohamed A
304 Shugri, Feven M Gebru.

305 8. REFERENCES

- 306 1. Lauer, B.J. and N.D. Spector, *Hyperbilirubinemia in the newborn*. Pediatrics in Review-Elk Grove,
307 2011. **32**(8): p. 341.
- 308 2. Slusher, T.M., et al., *Transcutaneous bilirubin measurements and serum total bilirubin levels in*
309 *indigenous African infants*. Pediatrics, 2004. **113**(6): p. 1636-1641.
- 310 3. Ekwochi, U., et al., *Pattern of morbidity and mortality of newborns admitted into the sick and*
311 *special care baby unit of Enugu State University Teaching Hospital, Enugu state*. Nigerian journal
312 of clinical practice, 2014. **17**(3): p. 346-351.
- 313 4. Ogunlesi, T.A. and O.B. Ogunfowora, *Predictors of acute bilirubin encephalopathy among*
314 *Nigerian term babies with moderate-to-severe hyperbilirubinaemia*. Journal of tropical
315 pediatrics, 2011. **57**(2): p. 80-86.
- 316 5. Kliegman, R.M., St Geme, J. W., *Nelson Textbook of Pediatrics E-Book*. 2019: Elsevier Health
317 Sciences.
- 318 6. Tikmani, S.S., et al., *Incidence of neonatal hyperbilirubinemia: a population-based prospective*
319 *study in Pakistan*. Tropical Medicine & International Health, 2010. **15**(5): p. 502-507.
- 320 7. Oteikwu Ochigbo, S., I. Venn, and K. Anachuna, *Prevalence of bilirubin encephalopathy in*
321 *Calabar, South-South Nigeria: a five-year review study*. Iranian Journal of Neonatology IJN, 2016.
322 **7**(1): p. 9-12.
- 323 8. Kokeb, M. and T. Desta, *Institution Based prospective cross-sectional study on patterns of*
324 *neonatal morbidity at Gondar University Hospital Neonatal Unit, North-West Ethiopia*. Ethiopian
325 journal of health sciences, 2016. **26**(1): p. 73-79.
- 326 9. Kassa, R.T., et al., *Neonatal Hyperbilirubinemia: Magnitude and Associated Etiologic Factors*
327 *among Neonates Admitted at Tikur Anbessa Specialized Hospital, Ethiopia*. Journal of Pregnancy
328 and Child Health, 2018. **05**.
- 329 10. Lake, E.A., et al., *Magnitude of Neonatal Jaundice and Its Associated Factor in Neonatal Intensive*
330 *Care Units of Mekelle City Public Hospitals, Northern Ethiopia*. International journal of pediatrics,
331 2019. **2019**.
- 332 11. Girma, M.T.H.H., *Prevalence and Contributing Factors of Neonatal Jaundice in Neonatal Intensive*
333 *Care Unit at St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia, 2019*.
334 Prevalence, 2020. **74**.
- 335 12. Mesić, I., et al., *Unconjugated pathological jaundice in newborns*. Coll Antropol, 2014. **38**(1): p.
336 173-8.
- 337 13. Aboyans, V. and C.o.D. Collaborators, *Global, regional, and national age-sex specific all-cause*
338 *and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the*
339 *Global Burden of Disease Study 2013*. The Lancet (British edition), 2015. **385**(9963): p. 117-71.

340